CXCL9 and dermatomyositis: During treatment with tofacitinib 11 mg/day of adults and children with refractory dermatomyositis, 50% of the patients experienced moderate improvement and 50% had minimal improvement and the mean change in the CDASI activity score over 12 weeks was statistically significant (since 28 ± 15.4 at baseline vs. 9.5 ± 8.5 at 12 weeks) (p = 0.0005) with the decreasing of serum chemokine levels of CXCL9/CXCL10 from baseline was demonstrated (31).